Form 4: Nautilus Biotech Grants Senior VP 160,000 Stock Options

Nautilus Biotechnology, Inc. granted its Senior VP of Product Development, Sankar Subramanian, 160,000 stock options with an exercise price of $2.32, vesting over several years.

Summary

• Sankar Subramanian, Senior VP of Product Development at Nautilus Biotechnology, Inc. (NAUT), was granted 160,000 stock options.
• The options have an exercise price of $2.32 per share.
• The earliest transaction date and date exercisable for these options is March 2, 2026.
• The options are set to expire on March 2, 2036.
• Vesting commenced on January 1, 2026, with 25% of the shares vesting on the one-year anniversary of this date.
• Following the initial 25% vesting, one thirty-sixth (1/36th) of the remaining shares will vest each month thereafter.
• Vesting is contingent upon Sankar Subramanian's continuous status as a "Service Provider" as defined in the Issuer's 2021 Equity Incentive Plan.
• Following this transaction, Sankar Subramanian beneficially owns 160,000 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event. While it's a routine compensation disclosure, the grant of options to a key executive aligns management's interests with long-term shareholder value, indicating confidence in future growth.

Positives

• The grant of stock options aligns the interests of Senior VP Sankar Subramanian with those of shareholders, incentivizing long-term company performance.
• Equity compensation is a standard method for attracting and retaining key talent in the biotechnology sector.

Negatives

• The options do not represent immediate cash value and their ultimate worth is dependent on the future stock performance of Nautilus Biotechnology, Inc.
• The vesting schedule means the options are not fully owned immediately and can be forfeited if employment ceases before full vesting.

Risks

• The value of the stock options is subject to the market price fluctuations of Nautilus Biotechnology, Inc.'s common stock.
• There is a risk of forfeiture if the reporting person's continuous status as a "Service Provider" is not maintained through each vesting date.

Future Outlook

The grant of stock options implies an expectation of future growth and value creation for Nautilus Biotechnology, Inc., as the options' value is tied to the company's stock performance over the long term.

Industry Context

StockSavvy.ai notes that equity compensation, such as stock option grants, is a prevalent practice in the biotechnology industry. It serves as a critical tool for attracting, retaining, and motivating key executives and scientific talent, aligning their long-term financial incentives with the company's success and shareholder value creation. This grant to a Senior VP of Product Development underscores the company's focus on innovation and product pipeline development.

Comparison to Industry Standards

• Equity compensation through stock options is a standard practice across the biotechnology and high-growth technology sectors, comparable to grants seen at companies like Illumina or Pacific Biosciences, which frequently use such incentives to retain top scientific and executive talent.
• The vesting schedule, with an initial cliff and subsequent monthly vesting, is a common structure designed to encourage long-term commitment and performance, aligning with typical industry benchmarks for executive equity grants.

Stakeholder Impact

• Shareholders: The grant of options to a Senior VP can be seen as a positive for shareholders, as it incentivizes management to drive long-term company performance and increase stock value.
• Employees: This type of equity grant is a common component of executive compensation packages, potentially signaling a stable and competitive compensation structure within the company.

Next Steps

• The stock options will vest according to the specified schedule, contingent on the reporting person's continued employment.
• The reporting person may choose to exercise the options at any time after they vest and before the expiration date, subject to company policy and blackout periods.

Key Dates

Keywords

Nautilus Biotechnology, NAUT, Stock Option, Insider Transaction, Form 4, Sankar Subramanian, Equity Incentive Plan, Vesting, Product Development